Bridgeway Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Bridgeway Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,667	Closed	-$366K	–	1302
2021 Q2	$366K	Hold	6,667	–	–	0.01%	1158
2021 Q1	$394K	Buy	+6,667	New	+$438K	0.01%	1162
2019 Q2	–	Sell	-493	Closed	-$103K	–	1333
2019 Q1	$103K	Hold	493	–	–	﹤0.01%	1277
2018 Q4	$86K	Sell	493 -4,198	-89%	-$838K	﹤0.01%	1315
2018 Q3	$1.06M	Buy	+4,691	New	+$758K	0.01%	857

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bridgeway Capital Management's CRBP Position: Q3 2021 in Review

Bridgeway Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q3 2021, closing a stake of 6,667 shares — an estimated $366K sold.

Bridgeway Capital Management first reported a position in CRBP in Q3 2018 and held it in 5 quarters. The position peaked at $1.06M in Q3 2018. 85 funds tracked by Wall St. Rank hold CRBP as of Q3 2021.

Bridgeway Capital Management reported no remaining Corbus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bridgeway Capital Management sold 6,667 Corbus Pharmaceuticals shares in Q3 2021, an estimated $366K.
Bridgeway Capital Management first reported a position in Corbus Pharmaceuticals in Q3 2018 and held it in 5 quarters.
Bridgeway Capital Management's Corbus Pharmaceuticals position peaked at $1.06M in Q3 2018.
85 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2021.

Based on Bridgeway Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.